Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial
默克(US:MRK) Businesswire·2025-11-08 19:30药物临床试验结果 - 公司研究性口服PCSK9抑制剂Enlicitide Decanoate在CORALreef Lipids三期试验中显著降低低密度脂蛋白胆固醇[1]